I’ve been stuck toggling between two frameworks for how autophagy fails in senescence, and frankly, I’m hitting a wall. On one hand, there’s the ULK1/2 rheostat model: the idea that the competitive phosphorylation of ULK1 at Ser757 (mTOR) versus Ser317/777 (AMPK) becomes chronically biased toward inhibition as we age. It’s a tidy narrative—metabolic inflexibility causing a failure of initiation. It paints aging as a signal transduction error.

But then there’s the Cystatin B titration hypothesis I brought up last week. If cytoplasmic cathepsin leakage isn't just a byproduct, but the primary driver of lysosomal ruin, then ULK1 failure might just be downstream collateral. If the cytosol is fundamentally hostile due to cathepsin dysregulation, no amount of re-balancing AMPK/mTOR crosstalk on the ULK1 scaffold is going to rescue a protease-depleted or ruptured autophagosome.

Here’s the rub: is the ULK1 bottleneck the cause of the collapse, or just the system’s futile attempt to compensate for failing distal machinery?

Let’s stress-test this:

• If we pharmacologically lock ULK1 in an active state, can we actually bypass a compromised lysosomal compartment?
• Does sustained AMPK-mediated ULK1 activation accelerate lysosomal exhaustion by overwhelming an already taxed system?
• Are we looking at a protein quality control failure (ULK1) or a compartmental containment failure (Cystatin B/Cathepsin)?

I’m leaning toward the latter as the more potent clinical target, but the signaling bias is just so much easier to quantify. If the lysosome is compromised, the cell is effectively blind to its own autophagy initiation status. I’m open to being wrong here—are we chasing a signaling ghost while the hardware is actually melting?